Alzheimer's Research
To learn more about Alzheimer’s, memory loss and ongoing clinical trials in this area, visit our Alzheimer’s Disease Research page.
Learn MoreThe purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).
Participant must have a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)
Participant must have good vein access, such that intravenous (IV) drug delivery or multiple blood draws would be able to be obtained
Participant must not be receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine
Participant must not have a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in longer than expected loss of consciousness
Participant must not have a history within the past 2 years of major depression or bipolar disorder
Participant must not have a history within the past 5 years of chronic alcohol or drug abuse/dependence
Participant must not have a known history of human immunodeficiency virus (HIV)
To learn more about Alzheimer’s, memory loss and ongoing clinical trials in this area, visit our Alzheimer’s Disease Research page.
Learn MoreTo learn more about neurological disorders and ongoing clinical trials in the area, visit our Neurological Disorders Research page.
A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.